Singapore markets close in 6 hours 11 minutes

Gyre Therapeutics, Inc. (GYRE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
10.84-0.04 (-0.37%)
At close: 04:00PM EDT
10.84 0.00 (0.00%)
After hours: 04:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.88
Open11.00
Bid10.63 x 100
Ask11.15 x 100
Day's range10.43 - 11.11
52-week range3.30 - 30.40
Volume48,923
Avg. volume64,644
Market cap926.929M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

    SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that the Center for Drug Evaluation (“CDE”) of China’s National Medical Products Administration (“NMPA”) has approved Gyre Pharmaceuticals’ (Gyre’s indirectly controlled subsidiary) Investigational New Drug (“IND”) application for F230 tablets, a selective endo

  • GlobeNewswire

    Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

    SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that it expects to be added to the small-cap Russell 2000® and all-cap Russell 3000® Indexes at the conclusion of the 2024 Russell Indexes annual reconstitution, effective after U.S. market close on June 28, 2024, according to a preliminary list of additions po

  • GlobeNewswire

    Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

    Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025 U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025 Acquired the rights to complementary assets relating to nintedanib through Gyre Pharmaceuticals to improve competitiveness in the PRC Cash and cash equivalents totaled $29.8 million as of Ma